{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:58:20Z","timestamp":1794567500282,"version":"4.9.1"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41579-025-01247-x","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:50:41Z","timestamp":1760349041000},"page":"183-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Bacterial cell envelope-targeting antibiotics"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4189-5803","authenticated-orcid":false,"given":"Charalampos","family":"Ntallis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8246-3006","authenticated-orcid":false,"given":"Nathaniel I.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7173-7355","authenticated-orcid":false,"given":"Andrew M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-8673","authenticated-orcid":false,"given":"Markus","family":"Weingarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1247_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi, M. et al. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404, 1199\u20131226 (2024).","journal-title":"Lancet"},{"key":"1247_CR2","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/S0140-6736(24)00876-6","volume":"403","author":"IN Okeke","year":"2024","unstructured":"Okeke, I. N. et al. The scope of the antimicrobial resistance challenge. Lancet 403, 2426\u20132438 (2024).","journal-title":"Lancet"},{"key":"1247_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01167-w","author":"U Theuretzbacher","year":"2025","unstructured":"Theuretzbacher, U., Jumde, R. P., Hennessy, A., Cohn, J. & Piddock, L. J. V. Global health perspectives on antibacterial drug discovery and the preclinical pipeline. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/s41579-025-01167-w (2025).","journal-title":"Nat. Rev. Microbiol."},{"key":"1247_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41586-024-07530-w","volume":"632","author":"K Lewis","year":"2024","unstructured":"Lewis, K. et al. Sophisticated natural products as antibiotics. Nature 632, 39\u201349 (2024).","journal-title":"Nature"},{"key":"1247_CR5","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance (WHO, 2024)."},{"key":"1247_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41579-019-0273-7","volume":"18","author":"CL Dulberger","year":"2019","unstructured":"Dulberger, C. L., Rubin, E. J. & Boutte, C. C. The mycobacterial cell envelope \u2014 a moving target. Nat. Rev. Microbiol. 18, 47\u201359 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1247_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nature22308","volume":"545","author":"MF Richter","year":"2017","unstructured":"Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299\u2013304 (2017).","journal-title":"Nature"},{"key":"1247_CR8","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202256033","volume":"24","author":"S Walesch","year":"2022","unstructured":"Walesch, S. et al. Fighting antibiotic resistance \u2014 strategies and (pre)clinical developments to find new antibacterials. EMBO Rep. 24, e56033 (2022).","journal-title":"EMBO Rep."},{"key":"1247_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrd2004","volume":"5","author":"E Breukink","year":"2006","unstructured":"Breukink, E. & de Kruijff, B. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5, 321\u2013323 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1247_CR10","doi-asserted-by":"publisher","first-page":"eaau5480","DOI":"10.1126\/science.aau5480","volume":"368","author":"BP Lazzaro","year":"2020","unstructured":"Lazzaro, B. P., Zasloff, M. & Rolff, J. Antimicrobial peptides: application informed by evolution. Science 368, eaau5480 (2020).","journal-title":"Science"},{"key":"1247_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389\u2013395 (2002).","journal-title":"Nature"},{"key":"1247_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41551-021-00801-1","volume":"6","author":"MDT Torres","year":"2021","unstructured":"Torres, M. D. T., Melo, M. C. R., Crescenzi, O., Notomista, E. & de la Fuente-Nunez, C. Mining for encrypted peptide antibiotics in the human proteome. Nat. Biomed. Eng. 6, 67\u201375 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1247_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","volume":"17","author":"NA Turner","year":"2019","unstructured":"Turner, N. A. et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat. Rev. Microbiol. 17, 203\u2013218 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1247_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1139\/cjc-2024-0040","volume":"102","author":"SD Taylor","year":"2024","unstructured":"Taylor, S. D. Synthesis, mechanism of action, and SAR studies on the cyclic lipopeptide antibiotic daptomycin. Can. J. Chem. 102, 414\u2013424 (2024).","journal-title":"Can. J. Chem."},{"key":"1247_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.abb.2011.10.018","volume":"517","author":"MD Hartley","year":"2012","unstructured":"Hartley, M. D. & Imperiali, B. At the membrane frontier: a prospectus on the remarkable evolutionary conservation of polyprenols and polyprenyl-phosphates. Arch. Biochem. Biophysics 517, 83\u201397 (2012).","journal-title":"Arch. Biochem. Biophysics"},{"key":"1247_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/271223a0","volume":"271","author":"GM Sheldrick","year":"1978","unstructured":"Sheldrick, G. M., Jones, P. G., Kennard, O., Williams, D. H. & Smith, G. A. Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine. Nature 271, 223\u2013225 (1978).","journal-title":"Nature"},{"key":"1247_CR17","unstructured":"Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996. MMWR Morb. Mortal. Wkly Rep. 46, 624\u2013626 (1997)."},{"key":"1247_CR18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1021\/acsinfecdis.2c00253","volume":"8","author":"E van Groesen","year":"2022","unstructured":"van Groesen, E., Innocenti, P. & Martin, N. I. Recent advances in the development of semisynthetic glycopeptide antibiotics: 2014\u20132022. ACS Infect. Dis. 8, 1381\u20131407 (2022).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR19","doi-asserted-by":"publisher","first-page":"10226","DOI":"10.1021\/acs.jmedchem.3c00565","volume":"66","author":"J Br\u010di\u0107","year":"2023","unstructured":"Br\u010di\u0107, J., Tong, A., Wender, P. A. & Cegelski, L. Conjugation of vancomycin with a single arginine improves efficacy against mycobacteria by more effective peptidoglycan targeting. J. Medicinal Chem. 66, 10226\u201310237 (2023).","journal-title":"J. Medicinal Chem."},{"key":"1247_CR20","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.4c17175","author":"MSTL Padilla","year":"2025","unstructured":"Padilla, M. S. T. L. & Nowick, J. S. Vancomycin\u2013teixobactin conjugates. J. Am. Chem. Soc. https:\/\/doi.org\/10.1021\/jacs.4c17175 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"1247_CR21","doi-asserted-by":"publisher","first-page":"22541","DOI":"10.1021\/jacs.4c06520","volume":"146","author":"HP Rahn","year":"2024","unstructured":"Rahn, H. P. et al. Biguanide-vancomycin conjugates are effective broad-spectrum antibiotics against actively growing and biofilm-associated Gram-positive and Gram-negative ESKAPE pathogens and Mycobacteria. J. Am. Chem. Soc. 146, 22541\u201322552 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"1247_CR22","doi-asserted-by":"publisher","first-page":"ii15","DOI":"10.1093\/jac\/dki005","volume":"55","author":"A Malabarba","year":"2005","unstructured":"Malabarba, A. & Goldstein, B. P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55, ii15\u2013ii20 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"1247_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.7164\/antibiotics.49.575","volume":"49","author":"RDG Cooper","year":"1996","unstructured":"Cooper, R. D. G. et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J. Antibiot. 49, 575\u2013581 (1996).","journal-title":"J. Antibiot."},{"key":"1247_CR24","doi-asserted-by":"publisher","first-page":"eabo4736","DOI":"10.1126\/scitranslmed.abo4736","volume":"16","author":"E van Groesen","year":"2024","unstructured":"van Groesen, E. et al. Semisynthetic guanidino lipoglycopeptides with potent in vitro and in vivo antibacterial activity. Sci. Transl. Med. 16, eabo4736 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1247_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455\u2013459 (2015).","journal-title":"Nature"},{"key":"1247_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41586-022-05019-y","volume":"608","author":"R Shukla","year":"2022","unstructured":"Shukla, R. et al. Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature 608, 390\u2013396 (2022).","journal-title":"Nature"},{"key":"1247_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16600-2","volume":"11","author":"R Shukla","year":"2020","unstructured":"Shukla, R. et al. Mode of action of teixobactins in cellular membranes. Nat. Commun. 11, 2848 (2020).","journal-title":"Nat. Commun."},{"key":"1247_CR28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1021\/acschembio.6b00295","volume":"11","author":"H Yang","year":"2016","unstructured":"Yang, H., Chen, K. H. & Nowick, J. S. Elucidation of the teixobactin pharmacophore. ACS Chem. Biol. 11, 1823\u20131826 (2016).","journal-title":"ACS Chem. Biol."},{"key":"1247_CR29","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1016\/j.cell.2023.07.038","volume":"186","author":"R Shukla","year":"2023","unstructured":"Shukla, R. et al. An antibiotic from an uncultured bacterium binds to an immutable target. Cell 186, 4059\u20134073.e27 (2023).","journal-title":"Cell"},{"key":"1247_CR30","doi-asserted-by":"publisher","first-page":"13579","DOI":"10.1002\/anie.202102224","volume":"60","author":"DA Wirtz","year":"2021","unstructured":"Wirtz, D. A. et al. Biosynthesis and mechanism of action of the cell wall targeting antibiotic hypeptin. Angew. Chem. Int. Ed. 60, 13579\u201313586 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1247_CR31","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/s41564-024-01696-9","volume":"9","author":"S Jekhmane","year":"2024","unstructured":"Jekhmane, S. et al. Host defence peptide plectasin targets bacterial cell wall precursor lipid II by a calcium-sensitive supramolecular mechanism. Nat. Microbiol. 9, 1778\u20131791 (2024).","journal-title":"Nat. Microbiol."},{"key":"1247_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jmb.2008.10.049","volume":"385","author":"PJ Loll","year":"2009","unstructured":"Loll, P. J. et al. Vancomycin forms ligand-mediated supramolecular complexes. J. Mol. Biol. 385, 200\u2013211 (2009).","journal-title":"J. Mol. Biol."},{"key":"1247_CR33","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.4c00835","author":"WS Lawrence","year":"2025","unstructured":"Lawrence, W. S. et al. Teixobactin: a resistance-evading antibiotic for treating anthrax. ACS Infect. Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00835 (2025).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1021\/acsmedchemlett.4c00215","volume":"15","author":"CR Jones","year":"2024","unstructured":"Jones, C. R., Lai, G. H., Padilla, M. S. T. L. & Nowick, J. S. Investigation of isobactin analogues of teixobactin. ACS Med. Chem. Lett. 15, 1136\u20131142 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"1247_CR35","doi-asserted-by":"publisher","first-page":"24855","DOI":"10.1021\/jacs.4c05138","volume":"146","author":"KC Ludwig","year":"2024","unstructured":"Ludwig, K. C. et al. The dual mode of antibacterial action of the synthetic small molecule DCAP involves lipid II binding. J. Am. Chem. Soc. 146, 24855\u201324862 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"1247_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108244118","volume":"118","author":"E Reithuber","year":"2021","unstructured":"Reithuber, E. et al. THCz: small molecules with antimicrobial activity that block cell wall lipid intermediates. Proc. Natl Acad. Sci. USA 118, e2108244118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR37","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1126\/science.102.2650.376","volume":"102","author":"BA Johnson","year":"1945","unstructured":"Johnson, B. A., Anker, H. & Meleney, F. L. Bacitracin: a new antibiotic produced by a member of the B. subtilis group. Science 102, 376\u2013377 (1945).","journal-title":"Science"},{"key":"1247_CR38","doi-asserted-by":"publisher","first-page":"14207","DOI":"10.1073\/pnas.1308268110","volume":"110","author":"NJ Economou","year":"2013","unstructured":"Economou, N. J., Cocklin, S. & Loll, P. J. High-resolution crystal structure reveals molecular details of target recognition by bacitracin. Proc. Natl Acad. Sci. USA 110, 14207\u201314212 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315310121","volume":"121","author":"NP Buijs","year":"2024","unstructured":"Buijs, N. P. et al. A classic antibiotic reimagined: rationally designed bacitracin variants exhibit potent activity against vancomycin-resistant pathogens. Proc. Natl Acad. Sci. USA 121, e2315310121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR40","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.1954.03690280018004","volume":"155","author":"G Genkins","year":"1954","unstructured":"Genkins, G. Bacitracin nephropathy. J. Am. Med. Assoc. 155, 894\u2013897 (1954).","journal-title":"J. Am. Med. Assoc."},{"key":"1247_CR41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41586-020-1990-9","volume":"578","author":"EJ Culp","year":"2020","unstructured":"Culp, E. J. et al. Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling. Nature 578, 582\u2013587 (2020).","journal-title":"Nature"},{"key":"1247_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jac\/dkh546","volume":"55","author":"JN Steenbergen","year":"2005","unstructured":"Steenbergen, J. N., Alder, J., Thorne, G. M. & Tally, F. P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55, 283\u2013288 (2005).","journal-title":"J. Antimicrob. Chemother."},{"key":"1247_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15257-1","volume":"11","author":"F Grein","year":"2020","unstructured":"Grein, F. et al. Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. Nat. Commun. 11, 1455 (2020).","journal-title":"Nat. Commun."},{"key":"1247_CR44","doi-asserted-by":"publisher","first-page":"E7077","DOI":"10.1073\/pnas.1611173113","volume":"113","author":"A M\u00fcller","year":"2016","unstructured":"M\u00fcller, A. et al. Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains. Proc. Natl Acad. Sci. USA 113, E7077\u2013E7086 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR45","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1021\/acsinfecdis.1c00316","volume":"7","author":"I Kotsogianni","year":"2021","unstructured":"Kotsogianni, I., Wood, T. M., Alexander, F. M., Cochrane, S. A. & Martin, N. I. Binding studies reveal phospholipid specificity and its role in the calcium-dependent mechanism of action of daptomycin. ACS Infect. Dis. 7, 2612\u20132619 (2021).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202114858","volume":"61","author":"R Moreira","year":"2021","unstructured":"Moreira, R. & Taylor, S. D. The chiral target of daptomycin is the 2R,2\u2032S stereoisomer of phosphatidylglycerol. Angew. Chem. Int. Ed. 61, e202114858 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1247_CR47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.93267","volume":"13","author":"P Machhua","year":"2025","unstructured":"Machhua, P. et al. Daptomycin forms a stable complex with phosphatidylglycerol for selective uptake to bacterial membrane. eLife 13, RP93267 (2025).","journal-title":"eLife"},{"key":"1247_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39486-8","volume":"13","author":"B Rimal","year":"2023","unstructured":"Rimal, B. et al. The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis. Sci. Rep. 13, 12227 (2023).","journal-title":"Sci. Rep."},{"key":"1247_CR49","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.bbamem.2014.05.014","volume":"1838","author":"T Zhang","year":"2014","unstructured":"Zhang, T., Muraih, J. K., MacCormick, B., Silverman, J. & Palmer, M. Daptomycin forms cation- and size-selective pores in model membranes. Bioch. Biophys. Acta Biomembranes 1838, 2425\u20132430 (2014).","journal-title":"Bioch. Biophys. Acta Biomembranes"},{"key":"1247_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.09.015","volume":"216","author":"D Beriashvili","year":"2018","unstructured":"Beriashvili, D. et al. Mechanistic studies on the effect of membrane lipid acyl chain composition on daptomycin pore formation. Chem. Phys. Lipids 216, 73\u201379 (2018).","journal-title":"Chem. Phys. Lipids"},{"key":"1247_CR51","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1021\/acs.jpcb.1c02047","volume":"125","author":"A Howe","year":"2021","unstructured":"Howe, A. & Sofou, S. Daptomycin-induced lipid phases on model lipid bilayers: effect of lipid type and of lipid leaflet order on membrane permeability. J. Phys. Chem. B 125, 5775\u20135785 (2021).","journal-title":"J. Phys. Chem. B"},{"key":"1247_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.12948","volume":"1354","author":"TT Tran","year":"2015","unstructured":"Tran, T. T., Munita, J. M. & Arias, C. A. Mechanisms of drug resistance: daptomycin resistance. Ann. N. Y. Acad. Sci. 1354, 32\u201353 (2015).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1247_CR53","doi-asserted-by":"publisher","first-page":"1035574","DOI":"10.3389\/fmolb.2022.1035574","volume":"9","author":"AH Nguyen","year":"2022","unstructured":"Nguyen, A. H., Hood, K. S., Mileykovskaya, E., Miller, W. R. & Tran, T. T. Bacterial cell membranes and their role in daptomycin resistance: a review. Front. Mol. Biosci. 9, 1035574 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"1247_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202403985","volume":"31","author":"R Makitrynskyy","year":"2024","unstructured":"Makitrynskyy, R. et al. Olikomycin A\u2013A novel calcium-dependent lipopeptide with antibiotic activity against multidrug-resistant bacteria. Chemistry 31, e202403985 (2024).","journal-title":"Chemistry"},{"key":"1247_CR55","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1021\/acsinfecdis.4c00810","volume":"11","author":"J Goodyear","year":"2024","unstructured":"Goodyear, J., Diamandas, M., Moreira, R. & Taylor, S. D. The calcium-dependent antibiotics: structure\u2013activity relationships and determination of their lipid target. ACS Infect. Dis. 11, 226\u2013237 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR56","doi-asserted-by":"publisher","DOI":"10.1128\/ecosalplus.ESP-0001-2018","author":"B Bertani","year":"2018","unstructured":"Bertani, B. & Ruiz, N. Function and biogenesis of lipopolysaccharides. EcoSal Plus https:\/\/doi.org\/10.1128\/ecosalplus.ESP-0001-2018 (2018).","journal-title":"EcoSal Plus"},{"key":"1247_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41579-019-0201-x","volume":"17","author":"BW Simpson","year":"2019","unstructured":"Simpson, B. W. & Trent, M. S. Pushing the envelope: LPS modifications and their consequences. Nat. Rev. Microbiol. 17, 403\u2013416 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1247_CR58","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1021\/la504407v","volume":"31","author":"LA Clifton","year":"2014","unstructured":"Clifton, L. A. et al. Effect of divalent cation removal on the structure of Gram-negative bacterial outer membrane models. Langmuir 31, 404\u2013412 (2014).","journal-title":"Langmuir"},{"key":"1247_CR59","doi-asserted-by":"publisher","first-page":"e01615-20","DOI":"10.1128\/mBio.01615-20","volume":"11","author":"CR MacNair","year":"2020","unstructured":"MacNair, C. R., Brown, E. D. & Dunman, P. Outer membrane disruption overcomes intrinsic, acquired, and spontaneous antibiotic resistance. mBio 11, e01615-20 (2020).","journal-title":"mBio"},{"key":"1247_CR60","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41579-023-00993-0","volume":"22","author":"CR MacNair","year":"2023","unstructured":"MacNair, C. R., Rutherford, S. T. & Tan, M.-W. Alternative therapeutic strategies to treat antibiotic-resistant pathogens. Nat. Rev. Microbiol. 22, 262\u2013275 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1247_CR61","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1021\/acsinfecdis.1c00482","volume":"8","author":"CR MacNair","year":"2022","unstructured":"MacNair, C. R. et al. Preclinical development of pentamidine analogs identifies a potent and nontoxic antibiotic adjuvant. ACS Infect. Dis. 8, 768\u2013777 (2022).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR62","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/jac\/dkm357","volume":"60","author":"AP Zavascki","year":"2007","unstructured":"Zavascki, A. P., Goldani, L. Z., Li, J. & Nation, R. L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60, 1206\u20131215 (2007).","journal-title":"J. Antimicrob. Chemother."},{"key":"1247_CR63","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","volume":"73","author":"SC Nang","year":"2021","unstructured":"Nang, S. C. et al. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol. Rev. 73, 679\u2013728 (2021).","journal-title":"Pharmacol. Rev."},{"key":"1247_CR64","doi-asserted-by":"publisher","first-page":"a025288","DOI":"10.1101\/cshperspect.a025288","volume":"6","author":"MJ Trimble","year":"2016","unstructured":"Trimble, M. J., Mlyn\u00e1r\u010dik, P., Kol\u00e1\u0159, M. & Hancock, R. E. W. Polymyxin: alternative mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 6, a025288 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1247_CR65","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/jm900999h","volume":"53","author":"T Velkov","year":"2009","unstructured":"Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure\u2212activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898\u20131916 (2009).","journal-title":"J. Med. Chem."},{"key":"1247_CR66","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1021\/acs.jcim.4c01574","volume":"65","author":"M Savenko","year":"2025","unstructured":"Savenko, M., V\u00e1cha, R., Ramseyer, C. & Rivel, T. Role of divalent ions in membrane models of polymyxin-sensitive and resistant Gram-negative bacteria. J. Chem. Inf. Modeling 65, 1476\u20131491 (2025).","journal-title":"J. Chem. Inf. Modeling"},{"key":"1247_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49200-5","volume":"15","author":"KR Buchholz","year":"2024","unstructured":"Buchholz, K. R. et al. Potent activity of polymyxin B is associated with long-lived super-stoichiometric accumulation mediated by weak-affinity binding to lipid A. Nat. Commun. 15, 4733 (2024).","journal-title":"Nat. Commun."},{"key":"1247_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33838-0","volume":"13","author":"S Manioglu","year":"2022","unstructured":"Manioglu, S. et al. Antibiotic polymyxin arranges lipopolysaccharide into crystalline structures to solidify the bacterial membrane. Nat. Commun. 13, 6195 (2022).","journal-title":"Nat. Commun."},{"key":"1247_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40275-0","volume":"14","author":"G Benn","year":"2023","unstructured":"Benn, G., Silhavy, T. J., Kleanthous, C. & Hoogenboom, B. W. Antibiotics and hexagonal order in the bacterial outer membrane. Nat. Commun. 14, 4772 (2023).","journal-title":"Nat. Commun."},{"key":"1247_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40276-z","volume":"14","author":"S Manioglu","year":"2023","unstructured":"Manioglu, S. et al. Reply to: antibiotics and hexagonal order in the bacterial outer membrane. Nat. Commun. 14, 4773 (2023).","journal-title":"Nat. Commun."},{"key":"1247_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-025-02133-1","author":"C Borrelli","year":"2025","unstructured":"Borrelli, C. et al. Polymyxin B lethality requires energy-dependent outer membrane disruption. Nat. Microbiol. https:\/\/doi.org\/10.1038\/s41564-025-02133-1 (2025).","journal-title":"Nat. Microbiol."},{"key":"1247_CR72","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65836","volume":"10","author":"A Sabnis","year":"2021","unstructured":"Sabnis, A. et al. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. eLife 10, e65836 (2021).","journal-title":"eLife"},{"key":"1247_CR73","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s42003-023-05302-2","volume":"6","author":"K Gadar","year":"2023","unstructured":"Gadar, K. et al. Disrupting iron homeostasis can potentiate colistin activity and overcome colistin resistance mechanisms in Gram-negative bacteria. Commun. Biol. 6, 937 (2023).","journal-title":"Commun. Biol."},{"key":"1247_CR74","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1128\/AAC.00756-12","volume":"56","author":"TR Sampson","year":"2012","unstructured":"Sampson, T. R. et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrobial Agents Chemother. 56, 5642\u20135649 (2012).","journal-title":"Antimicrobial Agents Chemother."},{"key":"1247_CR75","doi-asserted-by":"publisher","first-page":"001136","DOI":"10.1099\/mic.0.001136","volume":"168","author":"EVK Ledger","year":"2022","unstructured":"Ledger, E. V. K., Sabnis, A. & Edwards, A. M. Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort. Microbiology 168, 001136 (2022).","journal-title":"Microbiology"},{"key":"1247_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03205-z","volume":"9","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. The global distribution and spread of the mobilized colistin resistance gene mcr-1. Nat. Commun. 9, 1179 (2018).","journal-title":"Nat. Commun."},{"key":"1247_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02875-z","volume":"9","author":"CR MacNair","year":"2018","unstructured":"MacNair, C. R. et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat. Commun. 9, 458 (2018).","journal-title":"Nat. Commun."},{"key":"1247_CR78","doi-asserted-by":"publisher","first-page":"001104","DOI":"10.1099\/mic.0.001104","volume":"167","author":"M Humphrey","year":"2021","unstructured":"Humphrey, M. et al. Colistin resistance in Escherichia coli confers protection of the cytoplasmic but not outer membrane from the polymyxin antibiotic. Microbiology 167, 001104 (2021).","journal-title":"Microbiology"},{"key":"1247_CR79","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s41564-023-01369-z","volume":"8","author":"LA Carfrae","year":"2023","unstructured":"Carfrae, L. A. et al. Inhibiting fatty acid synthesis overcomes colistin resistance. Nat. Microbiol. 8, 1026\u20131038 (2023).","journal-title":"Nat. Microbiol."},{"key":"1247_CR80","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-021-04264-x","volume":"601","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. A naturally inspired antibiotic to target multidrug-resistant pathogens. Nature 601, 606\u2013611 (2022).","journal-title":"Nature"},{"key":"1247_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29234-3","volume":"13","author":"KD Roberts","year":"2022","unstructured":"Roberts, K. D. et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nat. Commun. 13, 1625 (2022).","journal-title":"Nat. Commun."},{"key":"1247_CR82","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1039\/D3MD00456B","volume":"14","author":"CJ Slingerland","year":"2023","unstructured":"Slingerland, C. J. et al. Semisynthetic polymyxins with potent antibacterial activity and reduced kidney cell toxicity. RSC Med. Chem. 14, 2417\u20132425 (2023).","journal-title":"RSC Med. Chem."},{"key":"1247_CR83","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1021\/acs.jmedchem.2c01344","volume":"66","author":"H-X Yang","year":"2023","unstructured":"Yang, H.-X. et al. Design, synthesis, and bioactivity investigation of cyclic lipopeptide antibiotics containing eight to nine amino acids. J. Med. Chem. 66, 2524\u20132541 (2023).","journal-title":"J. Med. Chem."},{"key":"1247_CR84","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1021\/acsinfecdis.3c00630","volume":"10","author":"CJ Slingerland","year":"2024","unstructured":"Slingerland, C. J. & Martin, N. I. Recent advances in the development of polymyxin antibiotics: 2010-2023. ACS Infect. Dis. 10, 1056\u20131079 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR85","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1021\/acs.jmedchem.0c02217","volume":"64","author":"J Li","year":"2021","unstructured":"Li, J. et al. Total and semisyntheses of polymyxin analogues with 2-thr or 10-thr modifications to decipher the structure-activity relationship and improve the antibacterial activity. J. Med. Chem. 64, 5746\u20135765 (2021).","journal-title":"J. Med. Chem."},{"key":"1247_CR86","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1021\/acs.jmedchem.2c01915","volume":"66","author":"NA Patil","year":"2023","unstructured":"Patil, N. A. et al. Critical role of position 10 residue in the polymyxin antimicrobial activity. J. Med. Chem. 66, 2865\u20132876 (2023).","journal-title":"J. Med. Chem."},{"key":"1247_CR87","doi-asserted-by":"publisher","first-page":"15878","DOI":"10.1021\/acs.jmedchem.2c01528","volume":"65","author":"CJ Slingerland","year":"2022","unstructured":"Slingerland, C. J. et al. Synthesis and evaluation of polymyxins bearing reductively labile disulfide-linked lipids. J. Med. Chem. 65, 15878\u201315892 (2022).","journal-title":"J. Med. Chem."},{"key":"1247_CR88","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1021\/acsinfecdis.9b00217","volume":"5","author":"P Brown","year":"2019","unstructured":"Brown, P. et al. Design of next generation polymyxins with lower toxicity: the discovery of SPR206. ACS Infect. Dis. 5, 1645\u20131656 (2019).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR89","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01940-24","volume":"69","author":"M Outeda-Garcia","year":"2025","unstructured":"Outeda-Garcia, M. et al. The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 69, e0194024 (2025).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1247_CR90","unstructured":"Spero Therapeutics. Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update. https:\/\/www.globenewswire.com\/news-release\/2025\/03\/27\/3050978\/0\/en\/Spero-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2024-Operating-Results-and-Provides-a-Business-Update.html (2025)."},{"key":"1247_CR91","doi-asserted-by":"publisher","first-page":"16109","DOI":"10.1021\/acs.jmedchem.3c01497","volume":"66","author":"X Jiang","year":"2023","unstructured":"Jiang, X. et al. Structure-interaction relationship of polymyxins with lung surfactant. J. Med. Chem. 66, 16109\u201316119 (2023).","journal-title":"J. Med. Chem."},{"key":"1247_CR92","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01563-23","volume":"68","author":"S Li","year":"2024","unstructured":"Li, S. et al. Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects. Antimicrob. Agents Chemother. 68, e0156323 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1247_CR93","doi-asserted-by":"publisher","first-page":"e01517-20","DOI":"10.1128\/AAC.01517-20","volume":"64","author":"AJ Lepak","year":"2020","unstructured":"Lepak, A. J., Wang, W. & Andes, D. R. Pharmacodynamic evaluation of MRX-8, a novel polymyxin, in the neutropenic mouse thigh and lung infection models against Gram-negative pathogens. Antimicrob. Agents Chemother. 64, e01517-20 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1247_CR94","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/antibiotics13040354","volume":"13","author":"X Qu","year":"2024","unstructured":"Qu, X. et al. Pharmacokinetics and nephrotoxicity of polymyxin MRX-8 in rats: a novel agent against resistant Gram-negative bacteria. Antibiotics 13, 354 (2024).","journal-title":"Antibiotics"},{"key":"1247_CR95","unstructured":"MicuRX. Pipeline. https:\/\/www.micurxchina.com\/en\/pipeline (2025)."},{"key":"1247_CR96","doi-asserted-by":"publisher","first-page":"e00200-17","DOI":"10.1128\/AAC.00200-17","volume":"61","author":"D Corbett","year":"2017","unstructured":"Corbett, D. et al. Potentiation of antibiotic activity by a novel cationic peptide: potency and spectrum of activity of SPR741. Antimicrob. Agents Chemother. 61, e00200-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1247_CR97","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1021\/acsinfecdis.9b00159","volume":"6","author":"S French","year":"2020","unstructured":"French, S. et al. Potentiation of antibiotics against Gram-negative bacteria by polymyxin B analogue SPR741 from unique perturbation of the outer membrane. ACS Infect. Dis. 6, 1405\u20131412 (2020).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR98","doi-asserted-by":"publisher","first-page":"e01239-17","DOI":"10.1128\/AAC.01239-17","volume":"61","author":"DV Zurawski","year":"2017","unstructured":"Zurawski, D. V. et al. SPR741, an antibiotic adjuvant, potentiates the in vitro and in vivo activity of rifampin against clinically relevant extensively drug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 61, e01239-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1247_CR99","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41564-020-0723-z","volume":"5","author":"M Song","year":"2020","unstructured":"Song, M. et al. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens. Nat. Microbiol. 5, 1040\u20131050 (2020).","journal-title":"Nat. Microbiol."},{"key":"1247_CR100","doi-asserted-by":"publisher","first-page":"119507","DOI":"10.1016\/j.bbamcr.2023.119507","volume":"1870","author":"A Sabnis","year":"2023","unstructured":"Sabnis, A. & Edwards, A. M. Lipopolysaccharide as an antibiotic target. Bioch. Biophys. Acta Mol. Cell Res. 1870, 119507 (2023).","journal-title":"Bioch. Biophys. Acta Mol. Cell Res."},{"key":"1247_CR101","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41586-023-06709-x","volume":"623","author":"L T\u00f6rk","year":"2023","unstructured":"T\u00f6rk, L., Moffatt, C. B., Bernhardt, T. G., Garner, E. C. & Kahne, D. Single-molecule dynamics show a transient lipopolysaccharide transport bridge. Nature 623, 814\u2013819 (2023).","journal-title":"Nature"},{"key":"1247_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50350-9","volume":"15","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Native mass spectrometry and structural studies reveal modulation of MsbA\u2013nucleotide interactions by lipids. Nat. Commun. 15, 5946 (2024).","journal-title":"Nat. Commun."},{"key":"1247_CR103","doi-asserted-by":"publisher","first-page":"117440","DOI":"10.1016\/j.ejmech.2025.117440","volume":"289","author":"H Wu","year":"2025","unstructured":"Wu, H. et al. Research progress of LpxC inhibitor on Gram-negative bacteria. Eur. J. Medicinal Chem. 289, 117440 (2025).","journal-title":"Eur. J. Medicinal Chem."},{"key":"1247_CR104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317274121","volume":"121","author":"DL Huseby","year":"2024","unstructured":"Huseby, D. L. et al. Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria. Proc. Natl Acad. Sci. USA 121, e2317274121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR105","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1126\/science.abi9009","volume":"374","author":"FA Th\u00e9lot","year":"2021","unstructured":"Th\u00e9lot, F. A. et al. Distinct allosteric mechanisms of first-generation MsbA inhibitors. Science 374, 580\u2013585 (2021).","journal-title":"Science"},{"key":"1247_CR106","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1021\/acs.jmedchem.1c01909","volume":"65","author":"VA Verma","year":"2022","unstructured":"Verma, V. A. et al. Discovery of inhibitors of the lipopolysaccharide transporter MsbA: from a screening hit to potent wild-type Gram-negative activity. J. Medicinal Chem. 65, 4085\u20134120 (2022).","journal-title":"J. Medicinal Chem."},{"key":"1247_CR107","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41564-024-01667-0","volume":"9","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii. Nat. Microbiol. 9, 1244\u20131255 (2024).","journal-title":"Nat. Microbiol."},{"key":"1247_CR108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119417119","volume":"119","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Re-sensitization of mcr carrying multidrug resistant bacteria to colistin by silver. Proc. Natl Acad. Sci. USA 119, e2119417119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR109","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1182749","volume":"327","author":"N Srinivas","year":"2010","unstructured":"Srinivas, N. et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010\u20131013 (2010).","journal-title":"Science"},{"key":"1247_CR110","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/antibiotics12030484","volume":"12","author":"D Li","year":"2023","unstructured":"Li, D. & Schneider-Futschik, E. K. Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis. Antibiotics 12, 484 (2023).","journal-title":"Antibiotics"},{"key":"1247_CR111","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-023-06799-7","volume":"625","author":"KS Pahil","year":"2024","unstructured":"Pahil, K. S. et al. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature 625, 572\u2013577 (2024).","journal-title":"Nature"},{"key":"1247_CR112","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","volume":"625","author":"C Zampaloni","year":"2024","unstructured":"Zampaloni, C. et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 625, 566\u2013571 (2024).","journal-title":"Nature"},{"key":"1247_CR113","doi-asserted-by":"publisher","first-page":"eaau2634","DOI":"10.1126\/sciadv.aau2634","volume":"4","author":"SU Vetterli","year":"2018","unstructured":"Vetterli, S. U. et al. Thanatin targets the intermembrane protein complex required for lipopolysaccharide transport in Escherichia coli. Sci. Adv. 4, eaau2634 (2018).","journal-title":"Sci. Adv."},{"key":"1247_CR114","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41589-020-00694-2","volume":"17","author":"F Fiorentino","year":"2020","unstructured":"Fiorentino, F. et al. Dynamics of an LPS translocon induced by substrate and an antimicrobial peptide. Nat. Chem. Biol. 17, 187\u2013195 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1247_CR115","doi-asserted-by":"publisher","first-page":"eadg3683","DOI":"10.1126\/sciadv.adg3683","volume":"9","author":"M Schuster","year":"2023","unstructured":"Schuster, M. et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Sci. Adv. 9, eadg3683 (2023).","journal-title":"Sci. Adv."},{"key":"1247_CR116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature17199","volume":"531","author":"Y Gu","year":"2016","unstructured":"Gu, Y. et al. Structural basis of outer membrane protein insertion by the BAM complex. Nature 531, 64\u201369 (2016).","journal-title":"Nature"},{"key":"1247_CR117","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1126\/science.aad3460","volume":"351","author":"J Bakelar","year":"2016","unstructured":"Bakelar, J., Buchanan, S. K. & Noinaj, N. The structure of the \u03b2-barrel assembly machinery complex. Science 351, 180\u2013186 (2016).","journal-title":"Science"},{"key":"1247_CR118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409672121","volume":"121","author":"TMA dos Santos","year":"2024","unstructured":"dos Santos, T. M. A. et al. Native \u03b2-barrel substrates pass through two shared intermediates during folding on the BAM complex. Proc. Natl Acad. Sci. USA 121, e2409672121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR119","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-019-1791-1","volume":"576","author":"Y Imai","year":"2019","unstructured":"Imai, Y. et al. A new antibiotic selectively kills Gram-negative pathogens. Nature 576, 459\u2013464 (2019).","journal-title":"Nature"},{"key":"1247_CR120","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-021-03455-w","volume":"593","author":"H Kaur","year":"2021","unstructured":"Kaur, H. et al. The antibiotic darobactin mimics a \u03b2-strand to inhibit outer membrane insertase. Nature 593, 125\u2013129 (2021).","journal-title":"Nature"},{"key":"1247_CR121","doi-asserted-by":"publisher","first-page":"11882","DOI":"10.1039\/D1SC02725E","volume":"12","author":"S Gro\u00df","year":"2021","unstructured":"Gro\u00df, S. et al. Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering. Chem. Sci. 12, 11882\u201311893 (2021).","journal-title":"Chem. Sci."},{"key":"1247_CR122","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41564-022-01227-4","volume":"7","author":"RD Miller","year":"2022","unstructured":"Miller, R. D. et al. Computational identification of a systemic antibiotic for Gram-negative bacteria. Nat. Microbiol. 7, 1661\u20131672 (2022).","journal-title":"Nat. Microbiol."},{"key":"1247_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52512-1","volume":"15","author":"D Sun","year":"2024","unstructured":"Sun, D. et al. The discovery and structural basis of two distinct state-dependent inhibitors of BamA. Nat. Commun. 15, 8718 (2024).","journal-title":"Nat. Commun."},{"key":"1247_CR124","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41586-019-1665-6","volume":"576","author":"A Luther","year":"2019","unstructured":"Luther, A. et al. Chimeric peptidomimetic antibiotics against Gram-negative bacteria. Nature 576, 452\u2013458 (2019).","journal-title":"Nature"},{"key":"1247_CR125","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1021\/acsinfecdis.2c00518","volume":"9","author":"A Javed","year":"2023","unstructured":"Javed, A. et al.\u00a0Chimeric peptidomimetic antibiotic efficiently neutralizes lipopolysaccharides (LPS) and bacteria-induced activation of RAW macrophages.\u00a0ACS Infect. Dis. 9, 518\u2013526 (2023).","journal-title":"ACS Infect. Dis."},{"key":"1247_CR126","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-024-07502-0","volume":"630","author":"KA Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz, K. A. et al. A Gram-negative-selective antibiotic that spares the gut microbiome. Nature 630, 429\u2013436 (2024).","journal-title":"Nature"},{"key":"1247_CR127","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-018-0483-6","volume":"561","author":"PA Smith","year":"2018","unstructured":"Smith, P. A. et al. Optimized arylomycins are a new class of Gram-negative antibiotics. Nature 561, 189\u2013194 (2018).","journal-title":"Nature"},{"key":"1247_CR128","unstructured":"World Health Organization. Global Tuberculosis Report 2019 https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf?ua=1 (2019)."},{"key":"1247_CR129","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois, V. A. & Rubin, E. J. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat. Rev. Microbiol. 20, 685\u2013701 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"1247_CR130","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","volume":"23","author":"M-L Wu","year":"2018","unstructured":"Wu, M.-L., Aziz, D. B., Dartois, V. & Dick, T. NTM drug discovery: status, gaps and the way forward. Drug Discov. Today 23, 1502\u20131519 (2018).","journal-title":"Drug Discov. Today"},{"key":"1247_CR131","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie, F. et al. Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387, 810\u2013823 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1247_CR132","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/14740338.5.2.231","volume":"5","author":"EJ Forget","year":"2006","unstructured":"Forget, E. J. & Menzies, D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 5, 231\u2013249 (2006).","journal-title":"Expert Opin. Drug Saf."},{"key":"1247_CR133","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","volume":"56","author":"CL Daley","year":"2020","unstructured":"Daley, C. L. et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur. Respiratory J. 56, 2000535 (2020).","journal-title":"Eur. Respiratory J."},{"key":"1247_CR134","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/ni.1781","volume":"10","author":"DG Russell","year":"2009","unstructured":"Russell, D. G., Cardona, P.-J., Kim, M.-J., Allain, S. & Altare, F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat. Immunol. 10, 943\u2013948 (2009).","journal-title":"Nat. Immunol."},{"key":"1247_CR135","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1128\/jb.172.3.1418-1423.1990","volume":"172","author":"V Jarlier","year":"1990","unstructured":"Jarlier, V. & Nikaido, H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J. Bacteriol. 172, 1418\u20131423 (1990).","journal-title":"J. Bacteriol."},{"key":"1247_CR136","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/jac\/dkr578","volume":"67","author":"R Nessar","year":"2012","unstructured":"Nessar, R., Cambau, E., Reyrat, J. M., Murray, A. & Gicquel, B. Mycobacterium abscessus: a new antibiotic nightmare. J. Antimicrob. Chemother. 67, 810\u2013818 (2012).","journal-title":"J. Antimicrob. Chemother."},{"key":"1247_CR137","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1574-6968.1994.tb07194.x","volume":"123","author":"V Jarlier","year":"1994","unstructured":"Jarlier, V. & Nikaido, H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol. Lett. 123, 11\u201318 (1994).","journal-title":"FEMS Microbiol. Lett."},{"key":"1247_CR138","doi-asserted-by":"publisher","first-page":"1331508","DOI":"10.3389\/fmicb.2024.1331508","volume":"15","author":"TQ Nguyen","year":"2024","unstructured":"Nguyen, T. Q. et al. Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches. Front. Microbiol. 15, 1331508 (2024).","journal-title":"Front. Microbiol."},{"key":"1247_CR139","doi-asserted-by":"publisher","first-page":"a021113","DOI":"10.1101\/cshperspect.a021113","volume":"5","author":"LJ Alderwick","year":"2015","unstructured":"Alderwick, L. J., Harrison, J., Lloyd, G. S. & Birch, H. L. The mycobacterial cell wall\u2014 peptidoglycan and arabinogalactan. Cold Spring Harb. Perspect. Med. 5, a021113 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1247_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46565-5","volume":"15","author":"IL Sparks","year":"2024","unstructured":"Sparks, I. L. et al. Lipoarabinomannan mediates localized cell wall integrity during division in mycobacteria. Nat. Commun. 15, 2191 (2024).","journal-title":"Nat. Commun."},{"key":"1247_CR141","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41573-024-00897-5","volume":"23","author":"V Dartois","year":"2024","unstructured":"Dartois, V. & Dick, T. Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. Nat. Rev. Drug Discov. 23, 381\u2013403 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1247_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300099","volume":"18","author":"S Yadav","year":"2023","unstructured":"Yadav, S. et al. DprE1 inhibitors: enduring aspirations for future antituberculosis drug discovery. ChemMedChem 18, e202300099 (2023).","journal-title":"ChemMedChem"},{"key":"1247_CR143","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1128\/JB.187.23.8020-8025.2005","volume":"187","author":"K Mikus\u030cova\u0301","year":"2005","unstructured":"Mikus\u030cova\u0301, K. et al. Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J. Bacteriol. 187, 8020\u20138025 (2005).","journal-title":"J. Bacteriol."},{"key":"1247_CR144","doi-asserted-by":"publisher","first-page":"8563","DOI":"10.1021\/acs.jmedchem.8b00281","volume":"61","author":"RV Chikhale","year":"2018","unstructured":"Chikhale, R. V., Barmade, M. A., Murumkar, P. R. & Yadav, M. R. Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis. J. Med. Chem. 61, 8563\u20138593 (2018).","journal-title":"J. Med. Chem."},{"key":"1247_CR145","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801\u2013804 (2009).","journal-title":"Science"},{"key":"1247_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56146-9","volume":"16","author":"A R\u00f6mpp","year":"2025","unstructured":"R\u00f6mpp, A. et al. The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis. Nat. Commun. 16, 826 (2025).","journal-title":"Nat. Commun."},{"key":"1247_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/app10072269","volume":"10","author":"V Makarov","year":"2020","unstructured":"Makarov, V. & Miku\u0161ov\u00e1, K. Development of macozinone for TB treatment: an update. Appl. Sci. 10, 2269 (2020).","journal-title":"Appl. Sci."},{"key":"1247_CR148","doi-asserted-by":"publisher","first-page":"9701","DOI":"10.1021\/jm401382v","volume":"56","author":"PS Shirude","year":"2013","unstructured":"Shirude, P. S. et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J. Med. Chem. 56, 9701\u20139708 (2013).","journal-title":"J. Med. Chem."},{"key":"1247_CR149","doi-asserted-by":"publisher","first-page":"e02020-19","DOI":"10.1128\/AAC.02020-19","volume":"64","author":"N Hariguchi","year":"2020","unstructured":"Hariguchi, N. et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor. Antimicrobial Agents Chemother. 64, e02020-19 (2020).","journal-title":"Antimicrobial Agents Chemother."},{"key":"1247_CR150","doi-asserted-by":"publisher","first-page":"e01586-16","DOI":"10.1128\/mBio.01586-16","volume":"8","author":"CA Kerantzas","year":"2017","unstructured":"Kerantzas, C. A., Jacobs, W. R., Rubin, E. J. & Collier, R. J. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. mBio 8, e01586-16 (2017).","journal-title":"mBio"},{"key":"1247_CR151","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1126\/science.aba9102","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science 368, 1211\u20131219 (2020).","journal-title":"Science"},{"key":"1247_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17202-8","volume":"11","author":"YZ Tan","year":"2020","unstructured":"Tan, Y. Z. et al. Cryo-EM structure of arabinosyltransferase EmbB from Mycobacterium smegmatis. Nat. Commun. 11, 3396 (2020).","journal-title":"Nat. Commun."},{"key":"1247_CR153","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.279.5347.98","volume":"279","author":"DA Rozwarski","year":"1998","unstructured":"Rozwarski, D. A., Grant, G. A., Barton, D. H. R., Jacobs, W. R. & Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98\u2013102 (1998).","journal-title":"Science"},{"key":"1247_CR154","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.1073\/pnas.1700062114","volume":"114","author":"Z Xu","year":"2017","unstructured":"Xu, Z., Meshcheryakov, V. A., Poce, G. & Chng, S.-S. MmpL3 is the flippase for mycolic acids in Mycobacteria. Proc. Natl Acad. Sci. USA 114, 7993\u20137998 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001370","volume":"19","author":"MK Waldor","year":"2021","unstructured":"Waldor, M. K. et al. Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport. PLoS Biol. 19, e3001370 (2021).","journal-title":"PLoS Biol."},{"key":"1247_CR156","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.str.2021.06.013","volume":"29","author":"O Adams","year":"2021","unstructured":"Adams, O. et al. Cryo-EM structure and resistance landscape of M. tuberculosis MmpL3: an emergent therapeutic target. Structure 29, 1182\u20131191.e4 (2021).","journal-title":"Structure"},{"key":"1247_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/srep43495","volume":"7","author":"G Degiacomi","year":"2017","unstructured":"Degiacomi, G. et al. Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression. Sci. Rep. 7, 43495 (2017).","journal-title":"Sci. Rep."},{"key":"1247_CR158","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17460441.2023.2218082","volume":"18","author":"EJ North","year":"2023","unstructured":"North, E. J., Schwartz, C. P., Zgurskaya, H. I. & Jackson, M. Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections. Expert Opin. Drug Discov. 18, 707\u2013724 (2023).","journal-title":"Expert Opin. Drug Discov."},{"key":"1247_CR159","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","volume":"144","author":"L Jia","year":"2009","unstructured":"Jia, L. et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80\u201387 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"1247_CR160","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113963119","volume":"119","author":"CM Stevens","year":"2022","unstructured":"Stevens, C. M. et al. Proton transfer activity of the reconstituted Mycobacterium tuberculosis MmpL3 is modulated by substrate mimics and inhibitors. Proc. Natl Acad. Sci. USA 119, e2113963119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR161","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.cell.2019.01.003","volume":"176","author":"B Zhang","year":"2019","unstructured":"Zhang, B. et al. Crystal structures of membrane transporter MmpL3, an anti-TB drug target. Cell 176, 636\u2013648.e13 (2019).","journal-title":"Cell"},{"key":"1247_CR162","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1016\/j.jmb.2020.05.019","volume":"432","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Structural basis for the inhibition of mycobacterial MmpL3 by NITD-349 and SPIRO. J. Mol. Biol. 432, 4426\u20134434 (2020).","journal-title":"J. Mol. Biol."},{"key":"1247_CR163","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tube.2018.10.008","volume":"113","author":"E Tenland","year":"2018","unstructured":"Tenland, E. et al. A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis. Tuberculosis 113, 231\u2013238 (2018).","journal-title":"Tuberculosis"},{"key":"1247_CR164","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.chembiol.2021.03.008","volume":"28","author":"G Martelli","year":"2021","unstructured":"Martelli, G. et al. N-Thio-\u03b2-lactams targeting L,D-transpeptidase-2, with activity against drug-resistant strains of Mycobacterium tuberculosis. Cell Chem. Biol. 28, 1321\u20131332.e5 (2021).","journal-title":"Cell Chem. Biol."},{"key":"1247_CR165","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s42003-024-06785-3","volume":"7","author":"M de Munnik","year":"2024","unstructured":"de Munnik, M. et al. Biochemical and crystallographic studies of l,d-transpeptidase 2 from Mycobacterium tuberculosis with its natural monomer substrate. Commun. Biol. 7, 1173 (2024).","journal-title":"Commun. Biol."},{"key":"1247_CR166","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1039\/D2SC06858C","volume":"14","author":"M de Munnik","year":"2023","unstructured":"de Munnik, M. et al. High-throughput screen with the l,d-transpeptidase LdtMt2 of Mycobacterium tuberculosis reveals novel classes of covalently reacting inhibitors. Chem. Sci. 14, 7262\u20137278 (2023).","journal-title":"Chem. Sci."},{"key":"1247_CR167","doi-asserted-by":"publisher","first-page":"101213","DOI":"10.1016\/j.drup.2025.101213","volume":"80","author":"S Ram\u00f3n-Garc\u00eda","year":"2025","unstructured":"Ram\u00f3n-Garc\u00eda, S. et al. Sanfetrinem, an oral \u03b2-lactam antibiotic repurposed for the treatment of tuberculosis. Drug Resist. Update 80, 101213 (2025).","journal-title":"Drug Resist. Update"},{"key":"1247_CR168","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202414325","author":"RD S\u00fcssmuth","year":"2025","unstructured":"S\u00fcssmuth, R. D., Kulike-Koczula, M., Gao, P. & Kosol, S. Fighting antimicrobial resistance: innovative drugs in antibacterial research. Angew. Chem. Int. Ed. https:\/\/doi.org\/10.1002\/anie.202414325 (2025).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1247_CR169","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1016\/j.cell.2024.05.013","volume":"187","author":"CD Santos-J\u00fanior","year":"2024","unstructured":"Santos-J\u00fanior, C. D. et al. Discovery of antimicrobial peptides in the global microbiome with machine learning. Cell 187, 3761\u20133778.e16 (2024).","journal-title":"Cell"},{"key":"1247_CR170","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1247_CR171","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41589-023-01349-8","volume":"19","author":"G Liu","year":"2023","unstructured":"Liu, G. et al. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii. Nat. Chem. Biol. 19, 1342\u20131350 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"1247_CR172","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531\u2013543 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1247_CR173","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1126\/science.adf5300","volume":"380","author":"M Klapper","year":"2023","unstructured":"Klapper, M. et al. Natural products from reconstructed bacterial genomes of the Middle and Upper Paleolithic. Science 380, 619\u2013624 (2023).","journal-title":"Science"},{"key":"1247_CR174","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41551-024-01201-x","volume":"8","author":"F Wan","year":"2024","unstructured":"Wan, F., Torres, M. D. T., Peng, J. & de la Fuente-Nunez, C. Deep-learning-enabled antibiotic discovery through molecular de-extinction. Nat. Biomed. Eng. 8, 854\u2013871 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1247_CR175","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1126\/science.1251652","volume":"343","author":"W K\u00fchlbrandt","year":"2014","unstructured":"K\u00fchlbrandt, W. The resolution revolution. Science 343, 1443\u20131444 (2014).","journal-title":"Science"},{"key":"1247_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06314-x","volume":"9","author":"J Medeiros-Silva","year":"2018","unstructured":"Medeiros-Silva, J. et al. High-resolution NMR studies of antibiotics in cellular membranes. Nat. Commun. 9, 3963 (2018).","journal-title":"Nat. Commun."},{"key":"1247_CR177","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41564-019-0604-5","volume":"5","author":"EN Parker","year":"2019","unstructured":"Parker, E. N. et al. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens. Nat. Microbiol. 5, 67\u201375 (2019).","journal-title":"Nat. Microbiol."},{"key":"1247_CR178","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/ph5111210","volume":"5","author":"JP Sarathy","year":"2012","unstructured":"Sarathy, J. P., Dartois, V. & Lee, E. J. D. The role of transport mechanisms in Mycobacterium tuberculosis drug resistance and tolerance. Pharmaceuticals 5, 1210\u20131235 (2012).","journal-title":"Pharmaceuticals"},{"key":"1247_CR179","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1073\/pnas.0709530105","volume":"105","author":"C Hoffmann","year":"2008","unstructured":"Hoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M. & Engelhardt, H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc. Natl Acad. Sci. USA 105, 3963\u20133967 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR180","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.1128\/JB.01919-07","volume":"190","author":"B Zuber","year":"2008","unstructured":"Zuber, B. et al. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J. Bacteriol. 190, 5672\u20135680 (2008).","journal-title":"J. Bacteriol."},{"key":"1247_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12718-4","volume":"7","author":"L Chiaradia","year":"2017","unstructured":"Chiaradia, L. et al. Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Sci. Rep. 7, 12807 (2017).","journal-title":"Sci. Rep."},{"key":"1247_CR182","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.tcsw.2020.100044","volume":"6","author":"SM Batt","year":"2020","unstructured":"Batt, S. M., Burke, C. E., Moorey, A. R. & Besra, G. S. Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall. Cell Surf. 6, 100044 (2020).","journal-title":"Cell Surf."},{"key":"1247_CR183","first-page":"226","volume":"10","author":"A Fleming","year":"1929","unstructured":"Fleming, A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenz\u00e6. Br. J. Exp. Pathol. 10, 226\u2013236 (1929).","journal-title":"Br. J. Exp. Pathol."},{"key":"1247_CR184","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1073\/pnas.54.4.1133","volume":"54","author":"DJ Tipper","year":"1965","unstructured":"Tipper, D. J. & Strominger, J. L. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl Acad. Sci. USA 54, 1133\u20131141 (1965).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1247_CR185","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","volume":"6","author":"K Bush","year":"2016","unstructured":"Bush, K. & Bradford, P. A. \u03b2-Lactams and \u03b2-lactamase inhibitors: an overview. Cold Spring Harb. Perspect. Med. 6, a025247 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01247-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:03:17Z","timestamp":1771333397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01247-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":185,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1038\/s41579-025-01247-x","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"22 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}